July 1 (UPI) -- Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial, the company announced. The vaccine, called mRNA-1010, was tested in a Phase 3 study in adults ages 50 and older. It worked better than a standard-dose flu vaccine, providing 26.6% more protection against the flu overall, the company said. In adults 65 and older, the vaccine showed a 27.4% improvement. "The severity of this past flu season underscores

Tag-uri: Coronavirus